Tilray Brands, Inc. — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Tilray Brands reported fiscal year 2026 (ended May 31, 2026) net revenue of $915.5 million, up 11% from $821.3 million in FY2025. Adjusted EBITDA increased to $61.1 million from $55.0 million (11% growth). International medical cannabis revenue grew 34%. The company completed the BrewDog acquisition, creating a $500 million pro forma beverage platform. Cash position strengthened to $235 million with net debt reduced to $0.7 million. FY2027 guidance projects adjusted EBITDA of $68–75 million and expects over $1 billion in annual revenue.
Why this rating
Record revenue and improving profitability metrics are positive, but company remains unprofitable on GAAP basis (−$105M net loss). BrewDog acquisition and beverage expansion are growth drivers. However, cannabis remains heavily regulated; U.S. rescheduling creates opportunity but regulatory uncertainty persists. $915M revenue is ~70% of $1.3B market cap; adjusted EBITDA of $61M is modest. Moderate trajectory impact for mid-cap cannabis firm.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.